Vertex Pharmaceuticals R&D decreased by 0.4% to $973.70M in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 2.5%, from $998.70M to $973.70M. Over 4 years (FY 2021 to FY 2025), R&D shows an upward trend with a 6.4% CAGR.
Analysis
StatementIncome Statement
SectionOperating Expenses
CategoryGrowth
SignalContext dependent
VolatilityStable
First reportedQ4 2013
Last reportedQ4 2025
How to read this metric
High spending signals a commitment to future growth and innovation, though it reduces current period earnings.
Detailed definition
Expenses related to the development of new products, services, and technologies, as well as the improvement of existing...
Peer comparison
Tech leaders often spend a significant percentage of revenue on R&D to prevent disruption by competitors.
Metric ID:
is_research_and_developmentHistorical Data
19 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.41B | $493.75M | $694.29M | $603.10M | $600.10M | $645.00M | $692.10M | $742.60M | $785.70M | $810.00M | $824.60M | $789.10M | $966.60M | $875.90M | $998.70M | $979.70M | $978.40M | $977.70M | $973.70M |
| QoQ Change | — | -64.9% | +40.6% | -13.1% | -0.5% | +7.5% | +7.3% | +7.3% | +5.8% | +3.1% | +1.8% | -4.3% | +22.5% | -9.4% | +14.0% | -1.9% | -0.1% | -0.1% | -0.4% |
| YoY Change | — | — | — | — | -57.4% | +30.6% | -0.3% | +23.1% | +30.9% | +25.6% | +19.1% | +6.3% | +23.0% | +8.1% | +21.1% | +24.2% | +1.2% | +11.6% | -2.5% |
Range$493.75M – $1.41B
CAGR-7.9%
Avg YoY Growth+11.0%
Median YoY Growth+19.1%
Current Streak4 quarters decline
R&D at Other Companies
Frequently Asked Questions
- What is Vertex Pharmaceuticals's r&d?
- Vertex Pharmaceuticals (VRTX) reported r&d of $973.70M in Q4 2025.
- How has Vertex Pharmaceuticals's r&d changed year-over-year?
- Vertex Pharmaceuticals's r&d decreased by 2.5% year-over-year, from $998.70M to $973.70M.
- What is the long-term trend for Vertex Pharmaceuticals's r&d?
- Over 4 years (2021 to 2025), Vertex Pharmaceuticals's r&d has grown at a 6.4% compound annual growth rate (CAGR), from $3.05B to $3.91B.
- What does r&d mean?
- The money spent on creating new technology and improving existing products.